Under the framework, apps connected to a medical device, such as one paired with an asthma inhaler, generally should be described in the drug’s official prescribing information, while standalone apps such as symptom trackers and dose reminders belong on the label only if the company can show the app is essential for safe and effective use or delivers a meaningful clinical benefit. In most cases, what a companion app shows its users will be treated as promotional material, the same way the agency handles other drug advertising. FDA officials said the guidance is meant to give developers a consistent, risk-proportionate pathway as companion software moves beyond simple reminders toward tools that adapt to each patient.
FDA finalises guidance on prescription drug companion apps
The US Food and Drug Administration on Tuesday released final guidance on prescription drug use-related software, setting out when an app sold alongside a medicine counts as drug labelling, when it must be named in the official prescribing information, and what companies must submit to the agency.
Why it matters: The guidance ends longstanding uncertainty for drugmakers building companion apps, drawing the line between promotional content and regulated labelling and deciding which apps become part of a drug's approved label.
Data as of FDA news release dated October 20, 2026, read in the live browser at fda.gov (the text fetcher returned a 404 for the same URL, which is why this item follows the earlier watcher run); the guidance title, Regulatory Considerations for Prescription Drug Use-Related Software, and its three clarifications are corroborated by an FDA official's public post of October 20, 2026. Developing item.
Sources
- FDA Issues Final Guidance on Prescription Drug Apps and Software - US Food and Drug Administration - 2026-10-20